Conditions:  ER+ Breast Cancer;  CCNE1 Amplification;  HER2-negative Breast Cancer;  Advanced Solid Tumor;  Ovarian Cancer;  Endometrial Cancer;  Gastric Cancer;  Esophageal Adenocarcinoma;  Carcinosarcoma
Interventions: Â Drug:Â BLU-222; Â Drug:Â Carboplatin; Â Drug:Â Ribociclib; Â Drug:Â Fulvestrant
Sponsor:  Blueprint Medicines Corporation
**RECRUITING NOW**
Interventions: Â Drug:Â BLU-222; Â Drug:Â Carboplatin; Â Drug:Â Ribociclib; Â Drug:Â Fulvestrant
Sponsor:  Blueprint Medicines Corporation
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
